

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>OXFORD BIOSCIENCE PARTNERS IV LP</u> _____ (Last) (First) (Middle) <u>222 BERKELEY STREET</u> _____ (Street) <u>BOSTON MA 02116</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ACAD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/02/2004</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/02/2004		C		2,291,667	A	(1)	2,291,667 ⁽²⁾	D	
Common Stock	06/02/2004		C		23,148	A	(1)	23,148 ⁽³⁾	D	
Common Stock	06/02/2004		P		282,169	A	\$7	2,573,836 ⁽²⁾	D	
Common Stock	06/02/2004		P		2,831	A	\$7	25,979 ⁽³⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series F Convertible Preferred Stock	(4)	06/02/2004		C		2,291,667		(5)	(6)	Common Stock	2,291,667 ⁽²⁾	(6)	0	D	
Series F Convertible Preferred Stock	(4)	06/02/2004		C		23,148		(5)	(6)	Common Stock	23,148 ⁽³⁾	(6)	0	D	

1. Name and Address of Reporting Person*
OXFORD BIOSCIENCE PARTNERS IV LP

 (Last) (First) (Middle)
222 BERKELEY STREET

 (Street)
BOSTON MA 02116

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MRNA FUND II LP

 (Last) (First) (Middle)
222 BERKELEY STREET

 (Street)
BOSTON MA 02116

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
OBP MANAGEMENT IV LP

 (Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

FLEMING JONATHAN

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BARNES JEFFREY T

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

CARTHY MARK

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

LYTTON MICHAEL

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

Explanation of Responses:

1. N/A - Securities were issued upon conversion of convertible preferred stock.

2. Securities held of record by Oxford Bioscience Partners IV L.P. ("OBP IV"). By virtue of their relationship as affiliated limited partnerships who share a general partner, mRNA Fund II L.P. ("mRNA") may be deemed to beneficially own the shares held of record by OBP IV. OBP Management IV L.P., as the general partner of OBP IV and mRNA may be deemed to beneficially own the shares held of record by OBP IV. Messrs. Fleming, Barnes, Carthy and Lytton as individual general partners of OBP Management IV L.P. may be deemed to beneficially own the shares held of record by OBP IV. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

3. Securities held of record by mRNA. By virtue of their relationship as affiliated limited partnerships who share a general partner, OBP IV may be deemed to beneficially own the shares held of record by mRNA. OBP Management IV L.P., as the general partner of OBP IV and mRNA may be deemed to beneficially own the shares held of record by mRNA. Messrs. Fleming, Barnes, Carthy and Lytton as individual general partners of OBP Management IV L.P. may be deemed to beneficially own the shares held of record by mRNA. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

4. 1-for-1

5. Immediate

6. N/A

Remarks:

[Oxford Bioscience Partners IV L.P., By: Jonathan J. Fleming](#) [06/02/2004](#)

[mRNA Fund II LP, By: Jonathan Fleming](#) [06/02/2004](#)

[OBP Management IV LP, By: Jonathan Fleming](#) [06/02/2004](#)

[Jonathan Fleming](#) [06/02/2004](#)

[Jeffrey T. Barnes](#) [06/02/2004](#)

[Mark P. Carthy](#) [06/02/2004](#)

[Michael E. Lytton](#) [06/02/2004](#)

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.